Professor in the Division of Cancer and Genetics at Cardiff University School of Medicine
Honorary Consultant Haematologist at University Hospital of Wales, Cardiff and Vale University Health Board

Professor Knapper trained in medicine at the University of Cambridge and Oxford University and later completed specialist haematology training in Cardiff. He is the haematological cancer lead at University Hospital of Wales and leads early phase haematological cancer trials and the regional acute leukaemia service. His clinical practice is predominantly in myeloid haematological cancers, particularly acute myeloid leukaemia and the myeloproliferative neoplasms.

Steven’s chief lab research interests lie in the development of targeted therapeutic agents in myeloid malignancies; both in pre-clinical laboratory studies and clinical research, including ‘back to bench’ laboratory projects running alongside clinical trials. He is currently Chief Investigator of the CRUK-funded phase 3 Optimise-FLT3 trial and recently Blood Cancer UK/Jacobsen Pharma-funded phase 3 OVATION study in acute promyelocytic leukaemia.

He is extensively involved in the development of clinical research at a national level as Deputy Chair of the UK AML Research Network and member of the UK Myeloproliferative Neoplasms Clinical Study Group. Other roles include Deputy Medical Director of the UK Trials Acceleration Programme, Joint Lead of the Cardiff CRUK Experimental Cancer Medicine Centre and Chair of the UK ECMC Haematology.